Protagonist Therapeutics Reports Acceptance Of Late-Breaking Abstract For Oral Presentation At 2023 European Hematology Association (EHA) Congress
Portfolio Pulse from Benzinga Newsdesk
Protagonist Therapeutics has reported the acceptance of a late-breaking abstract for an oral presentation at the 2023 European Hematology Association (EHA) Congress. The EHA will also feature two additional presentations from the company's rusfertide peptide therapeutic development program, including new data and updates in polycythemia vera.
June 06, 2023 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protagonist Therapeutics' late-breaking abstract has been accepted for an oral presentation at the 2023 EHA Congress, potentially increasing visibility and interest in the company's rusfertide peptide therapeutic development program.
The acceptance of Protagonist Therapeutics' late-breaking abstract for an oral presentation at the 2023 EHA Congress indicates that the company's rusfertide peptide therapeutic development program is gaining recognition in the medical community. This increased visibility and interest in the program could potentially lead to more partnerships, investments, or positive regulatory outcomes, which may positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100